Thymosin Alpha-1 dosage: clinical trial amounts

The HIV pilot regimen

The 12-week HIV pilot administered Thymosin Alpha-1 at 1.6 mg by subcutaneous injection twice weekly while participants continued highly active antiretroviral therapy. Subcutaneous means beneath the skin. The trial reported increased sjTREC levels, while absolute CD4 counts showed no significant difference at 12 weeks.

This is a Thymosin Alpha-1 dosage description I can actually make sense of: an amount attached to a population, another treatment, a duration and an outcome. Its repetition in other papers cannot establish a universal optimum.

Questions about thymosin alpha 1 dosing often ask for a single amount and a finish date. The published trial record describes the experiment; a clinician needs the person's records to make an individual treatment decision. This page gives no personal dosing advice.

Thymosin alpha 1 dosage protocol in sepsis

The ETASS severe-sepsis trial administered 1.6 mg subcutaneously every 12 hours for 5 days, then once daily for 2 days. Its mortality result was statistically marginal, with different analyses yielding different P values.

The TESTS phase 3 trial administered 1.6 mg subcutaneously every 12 hours for 7 days. It found no significant reduction in 28-day mortality. Both protocols were studied in critically ill adults receiving other care.

Leaving out the outcome discards half the experiment. The protocol tells us how the drug was investigated, including an investigation that failed to establish the hoped-for benefit.

Hepatitis and the broader dose range

The lamivudine combination literature used Thymosin Alpha-1 at 1.6 mg subcutaneously twice weekly in people with chronic hepatitis B. Their antiviral treatment continued as part of the comparison.

The comprehensive review reports single studied subcutaneous doses ranging from 0.8 to 6.4 mg. The range spans research contexts. It supplies no reason to select its midpoint, its largest amount or the most frequently repeated regimen for an individual.

The variety of studied amounts leaves my central question intact: which regimen yielded useful immune recovery in the people who received it?

Blood clearance and immune measurements

The review of pharmacology and clinical use describes an elimination half-life of approximately 2 hours after subcutaneous administration. Blood concentrations peak within about 1–2 hours and return toward baseline within about 24 hours. These are measurements of circulating peptide.

The HIV pilot assessed immune measurements over 12 weeks. The peptide's brief time in blood and a later cell measurement describe different parts of the experiment. The half-life describes clearance; it offers no tested onset of benefit or best administration time.

Thymosin alpha 1 injection preparations

Clinical studies largely used subcutaneous thymalfasin. The clinical review describes the synthetic peptide and its tolerability. Mild local irritation is the most familiar adverse effect.

Preparation quality remains separate from a study's numerical regimen. A research-labelled powder cannot inherit the identity, content or sterility checks of the clinical preparation by sharing its name. Mixing steps and self-administration instructions have no place in this record of trials.

The effects and safety page brings together the published cautions and U.S. status. The immune-reconstitution page follows the outcomes behind the HIV regimen.